Status:
COMPLETED
Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection
Lead Sponsor:
PowderMed
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the abi...
Detailed Description
Hepatitis B virus (HBV) is responsible for the most common form of parenterally transmitted viral hepatitis. It is estimated that approximately 350 million people worldwide are persistent carriers of ...
Eligibility Criteria
Inclusion
- Otherwise healthy, treatment naïve subjects with chronic well compensated, eAg positive HBV infection
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00277576
Start Date
January 1 2006
End Date
December 1 2007
Last Update
November 21 2008
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong
2
19/F Prince of Wales Hospital
Shatin, Hong Kong
3
Alice Ho Miu Ling Nethersole Hospital
Tai Po, N. T., Hong Kong
4
National University Hospital
Singapore, Singapore, 119074